

Ref. No: 074100521
From: Research
Date: 10/05/21
Subject: Dermatology department

REQUEST

I have a Freedom of Information request and I would greatly appreciate if you could answer the below three questions:

Q1. Could you please provide the numbers of patients treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Q2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

Q3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira

- Adalimumab Biosimilar
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Tofacitinib
- Ustekinumab
- Vedolizumab

RESPONSE

Pharmacy Response:

Q1: numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

ADALIMUMAB "AMGEVITA"	44
ADALIMUMAB "HUMIRA"	10
APREMILAST	59
APREMILAST INITIATION PACK	13
DIMETHYL FUMARATE	8
ETANERCEPT [:ENBREL 25mg]	* <5
GUSELKUMAB	* <5
IXEKIZUMAB	* <5
RISANKIZUMAB	* <5
SECUKINUMAB	* <5
USTEKINUMAB	25

Q2: Our records show zero (No) patients 16 years of age or under treated by Dermatology with the drugs listed above

Q3: numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

ADALIMUMAB "AMGEVITA"	99
ADALIMUMAB "HUMIRA"	* <5
GOLIMUMAB	7
INFLIXIMAB 'REMSIMA'	123
TOFACITINIB	* <5
USTEKINUMAB	48
VEDOLIZUMAB	53

* **Please note:** We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will

be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.